Announcing a new capability-Text analytics

We are pleased to announce our latest capability! Text, Voice and Data Analytics.  We have recently partnered with the Thoughtware Group to offer clients in our life science practice an advanced suite of tools to analyze large amounts of data in a quick and economical manner.  

"Big Data" is a term used by many in the industry today.  However, many in the space have failed to acheive an understanding of who says what and why.  For example, whenever marketers observe online digital communication, it remains unclear to them who the person is (interacting with their brand).  Secondly, these insights often remain largely disconnected from the "offline" understanding gained in consumer research. 

We aim to change this proposition by bridging the gap between what online digital communication promises to deliver and what it actually delivers.  With our unique "Thinking Insight" technology we can build segment specific analyses from any type of data feed (Text/Image/Voice) to evolve insights that connect the online and offline worlds.  This will help companies gain insight to the market faster, understand consumer reactions to their brand messages as well as identify new key opinion leaders for their company.

  
Advances in online and social media marketing are mainly focused today on data gathering, targeted advertising and general sentiment monitoring. This new partnership allows us to not only do these things, but when combined with our industry experts, the final product helps clients understand what they should do next with the information.  

The Data Miners' Date With The Supremes

And so it happened: The Supreme Court spent 70 minutes on Tuesday (4-27) hearing arguments about why Vermont’s data mining law should stay on the books, and why it shouldn’t.


This was a big deal – the major media outlets covered this event, all with a different take, which is always welcome and interesting. What we found especially remarkable was that none of them, and we read many stories, interviewed a Vermont physician. It was apparently the doctors themselves who initiated the legislation: When they found out their prescription data were being sold to the likes of IMS, they asked their legislators to write the legislation.


Most of the outlets quoted Justice Antonin Scalia, Chief Justice John Roberts and even Ruth Bader Ginsberg, who questioned the reasoning behind the legislation. They didn’t think it had much to do with protecting the First Amendment rights of the physicians, as Vermont’s legal staff claimed.


“The state is interested in promoting the sale of generic drugs and correspondingly to reduce the sale of brand-name drugs,” Justice Ginsburg said, according to the Washington Post. “And if that’s the purpose, why doesn’t that run up against what this court has said — that you can’t lower the decibel level of one speaker so that another speaker, in this case the generics, can be heard better?”

Critics of the law – which include many large physician groups and the New England Journal of Medicine -- contend that data mining “violates medical privacy” a core precept of the physician-patient relationship. They assert the data are private and that the law “advances state interest by closing gaps in medical privacy and protecting the patient-physician relationship from intrusion by sales people, who tend to promote newer, less-tested and more expensive brand name drugs.”


Which is fine: Except that the law also says that a physician can exclude his data, if he wants it that way.


Does pharma use this data to sell? Of course it does. Can a physician shut his door to a drug rep? Of course he can. Let us not forget that the transparency rules are in place.


We find it curious that industry critics have such little regard for physicians’ intelligence and willpower. 

The HCC, Its Priorities, and Financial Disclosure

The headline on the Healthcare Channel article reads: Did Merck conceal funding to a vocal advocate of Gardasil?

If Merck tried to, it did a lousy job. Its financial connection to oncologist Maura Gillison, the woman who linked the human papillomavirus with a new type of tonsil cancer, is readily available on the Web. The earliest connection we found goes back to a Forbes story, written in 2009. If Merck tried to keep the connection out of the story, it failed.

There might be an earlier mention, but there’s no date on this disclosure: Dr. Gillison, who also has a PhD, apparently spoke at a webinar for the Association of Reproductive Health Professionals. She disclosed that she “receives unrestricted educational grants from Merck and Digene.” 

If you haven’t guessed already, this is yet another dust-up over financial disclosure. The Healthcare Channel apparently was all aflutter that Dr. Gillison hadn’t listed Merck as a funding source when she published an article in the New England Journal of Medicine in 2010. It notified NEJM; the journal investigated, and it decided that Dr. Gillison HAD NOT violated any of its disclosure rules because the financial arrangement had fallen into a “gray area.”

We don’t know why NEJM let Dr. Gillison slide; but we think this is an example where we need to be careful about the generalizations associated with industry and healthcare practitioners' relationships.

The Healthcare Channel wrote: “The Healthcare Channel has exclusively learned that Dr. Gillison was in fact receiving payments from Merck, going back to 2008 that benefited at the least her laboratory, while she was at Johns Hopkins.” Maybe if its writers had surfed the Web for 15 minutes, they would have found what we found.

This is what the Merck Web page says regarding the information it discloses:

"On March 29, 2011, Merck updated its report on payments to U.S.-based medical and scientific professionals who speak on behalf of Merck about our products and other health care issues. These reports include legacy Merck products prior to the November 2009 merger between Merck and Schering-Plough. The new report covers payments made to speakers for the full year 2010. The report provides data for 2,088 physicians and other health care professionals who, on average, participated in 5.9 programs each and earned an average of $1,659 per program…"

Dr. Gillison is not listed. The presumption: She didn’t speak for Merck during 2010.

We all know there is no uniformity among the current disclosure laws, or among the industry members who are disclosing on Web sites. We’ll all have to wait for 2013 for that to happen.

This is what the Forbes article said about Dr. Gillison and Merck: “Gillison spent three years trying to draw Merck's attention to HPV tonsil cancer. Finally, she is working with Merck to design a study to see if Gardasil can affect HPV infection in the throat. Merck admits studying the problem is ‘challenging’ but says the potential is big.”

Here is a physician who made the connection between HPV, oral sex and a new form of throat cancer. She did the right thing: She worked with industry to try and find a cure. She never hid her connection with industry.

That old expression about throwing the baby out with the bathwater keeps popping into our brains ....

The Pooled CME Model: A True Gift

Industry members, the American Gastroenterological Association (AGA) has handed you a gift, even though you might be insulted by its recent proposal that you adopt a centrally funded CME model. From our back-of-the-envelope calculations, we can’t figure out how pharma loses with this proposition, only gains from it—including some public credibility.

But first, for those who don’t know what happened recently: The AGA proposed at a recent meeting that its pharma supporters contribute to a general fund for its CME activities. AN AGA education committee would determine the curriculum. But, “If required … AGA would guarantee companies to produce one program in a therapeutic area of interest to the supporter,” according to the Medical Marketing and Media article.

Industry members who heard the proposal weren’t exactly in love with the idea.

But, if they thought about it, they could at least grow to like it. One well known study has shown that physicians aren’t exactly aware of when industry has paid for the CME courses they’re taking, although they seem to be aware of the drug ads in the journals.

If the former is true, and it’s true that industry expects to recoup $3.56 for every dollar it invests in CME, then what difference does it make what the money pays for? Pharma only wins here. It is helping educate physicians, and it can say to its critics, “See, we are supporting well done CME and not involved in influence-peddling.”

Industry shouldn’t fear the change here—pharma should fear that it’s passing up a great opportunity to deal with a meddlesome transparency issue.

Transparency and Health Advocacy Organizations

The release of the American Journal of Public Health study [here’s the abstract ] showing that the vast majority of health advocacy organizations (HAO) did not reveal that they had received grants from an industry member raised the predicable media ruckus. The industry member was Lilly, and only because Lilly was the first member to disclose its HAO contributions. The study year was 2007 – four years ago.

According to the study, only 25 percent of the 161 groups – mainly mental health organizations -- acknowledged receipt of the money on their Web sites, and 10 percent admitted that Lilly was a sponsor. The concern, of course, is that the Sunshine Law only requires that industry members make public its financial arrangements with physicians –- not with nurses, not with HAOs. You can find the groups here.

We’ve decided to present another side of the picture, one other press outlets didn’t mention, at least that we could find.

Thomas Sullivan, who writes the blog Policy and Medicine, says the study is essentially skewed: it was funded, he says, by organizations and individuals he considers industry critics – the Pew Charitable Trusts, George Soros, the Rudin Family Association – who want to present this data “in a negative light."

Industry, he says, already has adopted transparency via the Sunshine Law. Forcing HAOs to do the same is wasting money and time. What is needed is more collaboration between industry and HAOs “to focus their research and development budgets on diseases and new breakthroughs.”

“While transparency is important and it should certainly be feasible for HAOs to disclose their corporate grants, the information and data must not be used to discredit the organizations or programs… that help improve health care for patients,” he writes. “However, that is exactly what Rothman’s [AJPH] article attempts to do.” The study asserts that the HAOs’ lack of transparency is “disappointing because [the grantees] ‘pursued activities that promoted the sale of Lilly products.’ But this claim is overstated.”

He continues. “What is really disappointing is that the authors use their anti-industry bias to present the HAO programs as marketing endeavors, when in reality, these programs taught patients and physicians how to treat deadly and chronic diseases, create a strategy to end breast cancer, and to utilize the latest breakthrough in medical science."

As we’ve written time and again, all industry-initiated financial transactions should be made public. What we hope for, but doubt is happening, is that all parties involved here -- industry, its critics, and so on -- are mindful of the unintended consequences of these actions.

KOLs, Background Checks, and Unintended Consequences

We look forward to the day when industry members will no longer have knee-jerk reactions to bad press – we just wish we had a reliable crystal ball to tell us when that will be.

Our bemusement stems from some members’ announcement that they now will conduct background checks on physicians – prior to their becoming consultants and speakers. This statement comes in the wake of ProPublica’s original story showing that some industry members hired physicians with tainted backgrounds. In the subsequent story, ProPublica only discusses the relatively serious infractions, like “prescribing unjustified or excessive medications and making serious medical errors.”

The industry members who made this announcement – AZ, Lilly, and Merck – did not provide lots of details on how these checks will be made, other than they plan to review state records. Nor did they discuss what kinds of infractions, if any, would be acceptable. One that comes to mind is failing to keep up with continuing medical education courses.

As we noted in a previous blog, the original ProPublica story found that of 17,700 thought leaders checked out, just 1.4%, or 250, were found to be tainted in some way. Of course, all industry members should have been looking at state and federal records from the get-go. This is something we encourage our clients to do as part of the normal contracting process.

A final thought: Will industry critics be happy with just a state and federal records check? Will they want something more intrusive? If so, we wonder if and how this will negatively impact the practice of medical research. We know this is the right thing to do, but what are the unintended consequences?  How will industry members change how they work with exceptionally influential KOLs?

Let us know what you think.

Patient Bloggers and the "T" Word

What an opportunity for industry to regain the public’s trust – or at least some of it.

We’re talking about industry’s use of social media to promote and market product, an excellent way to bypass mainstream media and hone the message. Even though the FDA is expected this month to present guidelines on how pharma can market medicines on Twitter, Facebook, and the like, the agency really has no say on what individual patient bloggers may say about their relationships with industry members.

To quote Pharma Marketing Blog's John Mack: “FDA cannot enforce transparency -- it has no authority over patients who are free to do and say what they like without mentioning any relationship they may have with pharma companies.”

According to Pew Research, about 61% of adults turn to the web for health information, and no doubt some of those people read those blogs. But do those bloggers disclose their relationship with pharma members, if one exists? We think they should.That is why like Sally Church (@maverickNY) we are going to create a disclosure section of this blog and our web site. Trust can be re-built one brick at a time.

And that goes for industry as well: The pharma member who ensures that the blogger discloses the connection is that much closer to establishing company loyalty among the readership.

It’s the T word, folks.  But stay tuned, because the storm around content creation in the industry is the next chapter in this story.  

The Midei Investigation: Get Your House in Order

Considering all the criticism against industry lately, this is not a good time for companies to be procrastinating about changing some of their business practices. Case in point: What an Abbott Labs division may be doing with Mark Midei, MD.  He is the cardiologist accused of implanting hundreds of more stents in patients than apparently were necessary.

When Dr. Midei was barred from his Baltimore-area hospital last year for allegedly performing the unnecessary surgeries, Abbott hired him as a consultant.

A Senate report -- investigating because of alleged Medicare fraud -- says that Abbott “showered” Dr. Midei with gifts and other handouts, and that he performed more stent surgeries than any other cardiologist in his area, suggesting that the two items are directly related. While we have discussed COI extensively in this blog, the Midei situation is yet another example of how industry needs to continually evaluate and update its contracts with Thought Leaders.


We think a big-name corporation is getting dragged into a situation it did not think was possible, but is becoming more the unintended consequential norm because of heightened scrutiny on the industry. Our advice to clients is get your house in order. Make sure your divisions and affiliates are reviewing their Thought Leader contracts.  Make sure you are taking the appropriate steps to improving your Sunshine Act compliance efforts.

If this is a challenge for you, let us help.

 

Pharma’s Wake-Up Call: More Individuals, More Often

Today’s topic of conversation: Why the DOJ has begun focusing on pharma execs -- and not just their companies.

Just recently, the feds announced they don’t want pharma executives doing business with the U.S. government if their company has been convicted of ripping off Medicare -- which is above and beyond existing legal restrictions.

According to the Washington Post, the new DHS guidelines say executives can be barred from doing business with the federal government from the time they knew about the fraud, or if the inspector general determines the executive should have known about the fraud.

And, in an unrelated, highly unusual move, the DOJ charged a former GSK attorney of various counts of fraud, alleging that she lied to federal authorities about what she knew regarding off-label promotion of Wellbutrin SR.

Let’s look at the numbers. According to these attorneys, who specialize in representing whistleblowers, “Over the past two years, the Department of Justice has collected over $2 billion from big pharmaceutical companies in fines, damages and civil penalties for defrauding Medicare and other health care programs funded with tax payer dollars.”
 That’s just the companies. Just think what the DOJ could collect if it also went after the execs. Think Jeff Skilling, Bernie Madoff, Michael Milken – who paid $600 million in fines for his financial sins.

According to the whistleblower attorneys, the DOJ doesn’t have to get personal. Under the False Claims Act, the offending pharma company could be forced to pay a $10,000 penalty for each script written under the offending scheme.

That’s certainly a lot of money – but it doesn’t have the same impact as being personally charged with a crime, or crimes.

"The current administration is feeling that they want to increase enforcement in this area, and they're of the belief that monetary settlements aren't sufficient, and they need to charge individuals to deter the conduct," Jeffrey Senger, former acting chief counsel with the FDA, told the Washington Post.

“The theme of [a] drug-law industry conference last month was ‘more individuals, more often,’” wrote the New York Times.

For those industry members who aren’t reading the writing on the wall, it’s either time to get new glasses or a very good translator.

Pharma, COI, and Principled Interactions

One thing’s for sure: Pharma members are going to need scorecards to keep track of what kind of industry-thought leader interaction each academic institution allows. For example, the University of Iowa does not permit the distribution of drug samples, nor can its faculty use ghostwriters. They can’t appear on speaker bureaus, either.

In Boston, physicians who work for Partners Healthcare – Brigham and Women’s Boston, Massachusetts General -- face similarly strict rules. If you recall, one Brigham faculty member resigned in protest over the fact that he could no longer earn money, speaking on behalf of pharma. But its rules on CME aren’t as stringent as those at Stanford University, or at Memorial Sloan Kettering, according to this same Globe article.

But at Yale, leadership there has adopted a more nuanced approach to dealing with perceived conflict of interest issues and interaction with industry.

“We rejected the idea that all interactions [with industry] are wrong and the notion that any relationship is a conflict of interest,” Ronald Vender, MD, chief medical officer for the Yale Medical Group and associate dean for clinical affairs for the Yale School of Medicine told Medical Marketing and Media. “[I]t's not that we are promoting interactions. But if one is going to have [them], we are promoting the concept of ‘principled interactions.'”
Well, what do you know -- a realistic approach. At Yale, these principled interactions require that faculty pay attention to the rules. Yale has established an “enforcement mechanism,” MM and M says.

Yale faculty must follow the rules regarding speakers’ bureaus, gifts, meals, interactions with sales reps, and so on. The one COI area that Yale put its foot down about is ghostwriting – it’s not allowed. Good for the Bulldogs. As we’ve said in this blog before, ghostwriting in this business is wrong. If a researcher needs an editor – and all writers need editors -- give that person credit at the end of the article.

About those scorecards. With academic institutions everywhere adopting new COI rules, the wise pharma member will want to know which institution requires what before making any contact with any institution. But who has time to get all that information? Maybe BioPharma Advisors can help you.

CBI KOL Management Conference-Princeton, NJ

We are attending the CBI KOL Management Conference in Princeton, NJ.  Click link for the agenda, follow our tweets by hashtag #kolmtg. 

We are part of Workshop presentation on Centralized KOL Management.  Send us an email if you would like a copy of that presentation

European Commission and Its Good Practice Recommendations

Et tu, EU? The European Commission has announced that it wants to see just how good a corporate neighbor pharma really is. The EC wants, says InPharm, “to examine corporate responsibility in the pharmaceutical industry with the aim of developing a series of good practice recommendations.”

What good corporate responsibility would entail seems to boil down to three areas, according to The Pharma Letter: ethics and transparency; access to drugs in Africa; and access to medicines in Europe. Further details, at least from scanning articles about this on the Web, are sketchy at best.

Are our European cousins piling on?

First, let’s define corporate responsibility. One definition says it’s “a voluntary approach that a business enterprise takes to meet or exceed stakeholder expectations by integrating social, ethical, and environmental concerns together with the usual measures of revenue, profit, and legal obligation. In another, it’s a “firm's sense of responsibility towards the community and environment ...

One says voluntary, the other says sense. Neither says obligatory. Are we suggesting that pharma should not be conscious of its moral and ethical obligations? Of course not. What we are suggesting -- and will continue to do so in this blog -- is that industry critics should be mindful of the unintended consequences of this constant drum-beat of criticism. (In the InPharm piece, the EC official does make note of pharma’s enormous economic contribution to the EU.)  As we have said again and again, let's focus on solving the problem!

Disruption of Research and Development of innovative medicines is serving no one!

Pharma Ethics: It’s Time for Constructive Ideas

The criticism of pharma continues. One of the latest salvos: “White Coat, Black Hat: Adventures on the Dark Side of Medicine,” by Carl Elliott, MD, professor at the Center for Bioethics at the University of Minnesota. In an interview with Pharmalot, Dr. Elliott spoke about industry ethics, and said that industry money has undermined trust. “The difficulty with the way things are done now is that you don’t know if you can believe what’s in the medical literature anymore,” he said.

His views on transparency: “I don’t think disclosure solves the problem. That seems to be the approach and I think it’s totally misguided. The more doctors who do it and the more widely known people know about it, the more widely it will be done and the practice will become normalized and nobody will feel any compunction about taking money from industry anymore.”

I think Dr. Elliott is right -- maybe time can correct some of these problems. Maybe some of the recently implemented regulations and the court proceedings will change poor behavior. 

But, friends, the criticism leveled at industry hasn’t been exactly constructive. What's needed are suggested solutions. We still do not have answers, we need operational leadership on where to go from here. We continue to suggest that we all move beyond the "industry/HCP relationship is dirty."  We suggest that you cannot highlight a problem unless you also offer a solution going forward.

Pharma: Is It Time To Answer the Critics?

It’s a question that’s begging to be asked: How can pharma get its groove back? Bad news, much of it self-inflicted, continues to besiege it. There’s the Pharmalot DOJ whistleblower’s story, which said that eight of the ten largest healthcare fraud cases involved drug makers. Says Pharmalot: “The scrutiny has been eating away at pharma’s reputation and gradually forcing changes in business practices. But attorneys say many more lawsuits are in the pipeline and the willingness of the federal government to pursue them - selectively - remains unabated.”

Then there is the ProPublica story. Reporters at ProPublica used industry-compiled databases containing the names of physicians and other thought leaders who have spoken on behalf of pharma and checked them out. What they found: Not all the thought leaders are worthy of the job. Some weren’t board certified. Others had “serious sanctions."

It sounds ugly. But if you do the math, it’s a small percentage: of 17,700 thought leaders checked out, 1.4% -- 250 — were found to be tainted in some way. (The story says more than 250, but doesn’t give a specific number.)

On the one hand: Some industry members interviewed by ProPublica reporters admitted that they didn’t do the background checks that they should have.

On the other: That 1.4% wasn’t in the story, but it doesn’t matter. The PR damage continues to be inflicted -- from within, and without.

In 1970, an American man or woman could expect to celebrate a 71st birthday. In 2003, that person could expect to live another 6 years or so. Pharmaceutical, Biotech & Medical Devices are a huge reason for those extra years. But few people – including pharma itself – seem to acknowledge that truth. Kinda of like some in Congress & the administration who do not take pride in the Healthcare Reform act. While Americans do not like this large entitlement program, in general we believe overall healthcare of the US population will be more improved.

Maybe it's time for pharma and others to speak up? Maybe. Being silent sure hasn’t helped the industry (or even the Democratic Congress for that matter).

Financial Disclosures and Journal Authors: Enough Rhetoric

When President Obama signed the healthcare reform act into law, part of the legislation package included the Physicians Payment Sunshine Act. We’re all familiar with it. Sometime soon, Industry will have to make public its financial transactions with industry consultants.

So, why are the media still acting like every undisclosed transaction – especially ones that are years old -- between physician and industry is like an unheard-of immoral outrage? Case in point: the 2007 study showing that 25 of 32 consultants to medical device companies didn’t reveal their connections in published journal articles. Those connections were worth millions, the Times says.

A constant critic of the industry-thought leader connection was quoted as saying that the study was “one more indication of the widespread corruption of the medical profession by industry money.”

It’s not clear from the article how many journals were involved in the study. The study apparently doesn’t name individual doctors or their articles. Two journal editors were quoted, each saying that yes, they must get stricter on disclosures. We’re not sure how these journals are funded, but if those sources are medical device companies, it won’t be easy biting the hand that feeds them.

We support transparency – our blog readers know this.

We do not support incomplete journalistic reporting – a check on even some of these journals in 2008, 2009, and 2010 would have rounded out the story. What were their disclosure records then? Did disclosure improve, stay the same, get worse? Is there a basis for comparison? If this record check did happen, it’s not mentioned in the Times article.

The article quotes the study’s author as saying he didn’t “know how often the journals required disclosures in 2008, but he said the lack of results showed ‘a broken system’ regardless of who was to blame.”

Physicians have battled over the question of financial disclosure for years – this NEJM editorial is from 1993.

Again, the unintended consequences of this constant, where-is-this-getting-us criticism: The effect on physician education! Physicians need to be educated in the latest research, newest drugs, newest medical devices. Industry use to be a trusted source of that information. Could we tone down the rhetoric, and begin a conversation?  We have to figure out solutions that improve healthcare overall and continue to recognize the value of medical innovation.

Ghostwriting and Full Disclosure: When the Critics Get Caught

A friend and I were discussing the problem of ghostwriting in industry – she was lamenting its demise. My friend, a journalist by profession, didn’t see a conflict of interest problem – she saw a conflict with clarity problem. She had worked for one of the major pharma houses, and one of her jobs was helping a researcher with writing his papers. Scientists generally can’t write, she said.

Anybody who writes for a living who’s seen what a researcher can do to the English language will agree with her. By definition, a ghostwriter is someone who writes for another – he or she doesn’t alter thoughts, tone, meaning, wit. The ghostwriter just makes the prose clear. BioPharma Advisors even uses ghostwriters for some of its own work.


Which brings us to the Wyeth, Prempro, Adriane Fugh-Berman, PLoS Medicine, conflict-of-interest drama. Wyeth (now part of Pfizer) is being sued by women who took the HRT Prempo and contracted breast cancer. The drug maker recently was slammed by Fugh-Berman in PLoS for hiring a communications firm, DesignWrite, to “ghostwrite” articles that touted Prempro’s benefits and smoothed over the risks. These documents – more than ghostwritten -- had been released as part of the court record.

But it was no coincidence that Fugh-Berman wrote the piece, and that PLoS published it. Fugh-Berman, at the time her article was written, was on the payroll of the plaintiff’s law firm. That fact wasn’t disclosed in the article. Another hidden bit of info: PLoS had sued Wyeth for the DesignWrite documents.

Fugh-Berman told Pharmalot that she had never made a secret about her status as an expert witness, and would clarify her position. PLoS editor Ginny Barbour told Pharmalot, “We intervened in the Prempro case solely because of our interest in unmasking this [ghostwriting] practice. We have no professional, financial, legal or other relationship with the plaintiffs or their lawyers in any of the cases that Wyeth is defending, or in any other past or ongoing legal case." Checking Google, very few media outlets covered this part of the story, compared to the splash the PLoS article made. We continue to lament the media’s current lack of parity in covering industry.

The DesignWrite articles ran between 1997 and 2003. Did Wyeth do the right thing? No. Are there reasons that nearly all crimes have a statute of limitations? Yes.

Pharma has said that ghostwriting, as done in the past, will stop. And it should in the context in which it is currently practiced, for at least two reasons: One, it’s not completely transparent. Two, as long as pharma continues to make itself a target, it will be guilty until proven innocent, and its research will continue to be viewed skeptically, and that affects us all.

But please, pharma members – for your researchers who can’t write, hire an editor, and give the guy or gal credit at the article’s end for work done.

Pharma and University Collaborations: On the Rise

Pharma members and university researchers have increasingly formed collaborative partnerships to develop new medicines, according to a Business Insights report.

But you don’t need a report to tell you that. Just one media account, like this FierceBiotech story – about AstraZeneca and the University College of London --
tells you there are many other collaborations right behind it. AZ and University College signed a three-year deal to create drugs that use stem cells to mend the damaged eyesight of those with diabetes. GSK also has a deal with University College. 

A quick rundown of reasons for these partnerships: Pharma needs fast and furious ways to beat patent expirations; all the low-hanging, cheap developmental fruit’s been picked; and the remaining developmental fruit is costing, and will continue to cost, huge amounts of money. As for why the universities are signing on, they need cash too – endowments are down, public financial support is down. Both sides have good reasons to partner up. 

There’s every reason to think that good outcomes can happen. Consider the trove of information -- all being shared -- recently uncovered about Alzheimer’s disease when academia, government, and pharma researchers collaborated. 

But on second thought: We shouldn’t be too hopeful. It’s likely just a matter of time before pharma critics start complaining about these collaborations. 

For what legitimate reason? We've no idea.

The Nemeroff Affair

The Charles Nemeroff/Tom Insel affair is noteworthy for a few reasons.

1. If there are clear rules, there are no excuses

2. People in high places do really stupid things, so companies need to be concerned about good Thought Leader management practices.

3. Situations like these make it more difficult for companies to navigate the current conflict of interest issue, so understand what is happening in the marketplace around you and have plans to adapt to those conditions.

To recap: If you’ll recall, psychiatrist Charles Nemeroff, former chair of Emory University’s school of medicine’s psychiatry department, left Emory under less than auspicious circumstances. While there, he was receiving NIH funding – but was also getting lots of funding from pharmaceutical companies for speaker services – a major faux pas under NIH regulations. After a U.S. Senate Finance Committee embarrassed Emory with the information, Emory more than slapped Nemeroff’s hands. It told its star M.D. he could not apply for any grants for two years. For his part, Nemeroff claimed the conflict of interest rules were ambiguous.

Enter Insel, the National Institute of Mental Health director, and a former Nemeroff colleague at Emory. Insel received a call regarding Nemeroff from a potential employer, the University of Miami – which obviously wanted a reference. Insel did speak with Pascal Goldschmidt, dean and senior VP of the Leonard M. Miller School of Medicine at UM. But what was said?

Insel’s actions have a lot of people scratching their heads -- considering the current climate --  so much so that Insel wrote about it on his blog. Insel claims that all he did was answer a question about whether Nemeroff could apply for grants – but Goldschmidt easily could have gotten that information elsewhere, and Insel admits that he should have sent Goldschmidt elsewhere for the answer.

The U of M says it will keep an eye on Nemeroff. “There will be particular scrutiny of his activities to protect him and the institution and to [make] sure there is no bias in his work,” said Goldschmidt.

The take-home lessons here: Industry needs to manage its Though Leader relationships much closer and adapt to what will certainly be an ever-changing set of rules, regulations, and market conditions.

Is the Conflict of Interest Tide Turning?

Though we want to imagine physicians as mild-mannered healers, we can’t help but think that some medications would have helped at the recent meeting between folks at the ACCME and the AHA – the one where the ACCME kinda, sorta didn’t reverse its public stance about not letting industry scientists speak at CME-accredited AHA meetings.

Though they won’t admit it.

"We have definitely not reversed course," Murray Kopelow, chief executive of the ACCME, told the Milwaukee Journal Sentinel.

One week industry scientists can’t speak at an accredited event, two weeks later, they can? What happened in between? What should have been happening since the conflict of interest issue first reared its head – a conversation among doctors, on both sides of this debate. Up until now, it’s been the purists’ voices who have dominated the conversation. But after the ACCME announced its decision a few weeks ago, people like Francis Collins and Clyde Yancy objected.

“It is a breathtaking sweep to squash something that is really important to us, the science going on in the private sector,” said Collins, who runs the NIH.

It was Yancy, president of the AHA, who met with Kopelow after the ACCME’s sweeping announcement in mid-June. According to Medical Marketing and Media, Yancy told the ACCME that his group had its own “independent peer-review process and procedure for accepting abstracts.” Apparently, that was good enough for the ACCME. The ACCME now will allow industry scientists to speak at accredited events, as long as the accreditor – the AHA, whoever – has control of the information being discussed.  Yancy brought up another interesting point in the MM and M article – he said industry abstracts presented at meetings are far and few between. “Over the last three years, only about one-half of one percent of abstracts at AHA's annual confabs have been presented by industry scientists. … which is pretty interesting when you consider all the hand-wringing that's taken place as of late.”

Did the ACCME cave to big-name pressure? Maybe, maybe not. What this scene reveals is that those physicians who are not happy about being labeled guilty until proven innocent should say so. It also reveals that when some physicians say, “hey wait a minute, let’s use some common sense,” others might actually agree with them.

We’d Rather Be Writing About Something Else

We wouldn’t be writing about the showdown going on between Zimmer Holdings and its former star orthopedic surgeon if good Thought Leader development principles had been in place.

To recap: Dr. Richard A. Berger, who was a long-time consultant for Zimmer, is publicly biting the hand that formerly fed him, angry that the medical device company did not pay attention to data he had collected, showing a knee replacement device failed prematurely. In a statement that it gave to the New York Times, Zimmer said it had investigated Zimmer’s complaints, and said “he had disagreed with its findings.” According to the Times, Berger, of Rush University Medical Center in Chicago, presented his findings at two meetings of the American Association of Orthopedic Surgeons. Patient complaints started coming in four years ago, a year after he implanted this particular model, according to Berger.

There is the usual back and forth: Zimmer blames Berger’s technique, Berger counters with – I was a star, now I’m the problem? Zimmer says this particular model was a success – but doesn’t have “separate test data … because the F.D.A. had not required the company to study it in patients before selling it,” to quote the Times. 

Should the situation have come to this? We suggest that had an active Thought Leader management process been in place, this issue could have been resolved and managed in a manner that could have had the same outcome, but without all the acrimony.And, for those of us who think having objective data showing a medical device works before it’s inserted into our bodies is a good idea, there is hope: the FDA is entertaining the notion of tightening the medical devices' approval standards. That will benefit patients.




Yes, these approval standards will mean more time spent on design and implementation -- which will increase the cost of bringing the product to market, which, overall, may not be a bad thing. At a recent town meeting between FDA officials and medical device professionals, the latter said current regulations lack clarity and are threatening the “survival of some venture-backed companies."

Wow. A win-win situation! Doesn’t happen too often, but it could with the right kind of management approach.